BiotechTube
ThinkCyte

ThinkCyte

Tokyo, Japan· Est.

ThinkCyte develops AI-driven, label-free cell sorting technology for accelerating drug discovery and cellular therapy development.

thinkcyte.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

ThinkCyte develops AI-driven, label-free cell sorting technology for accelerating drug discovery and cellular therapy development.

OncologyImmunologyRegenerative Medicine

Technology Platform

Ghost Cytometry: A label-free, high-throughput cell analysis and sorting technology that uses structured illumination to capture high-dimensional morphological waveforms, which are classified in real-time by AI.

Opportunities

Significant growth opportunity in providing label-free, AI-enhanced tools for cell therapy manufacturing QC and phenotypic drug discovery, markets that are expanding rapidly.
The cloud-based MorphoScan platform offers a scalable software revenue model.

Risk Factors

Competition from established flow cytometry giants and the challenge of convincing researchers to switch from well-understood, label-based methods to a novel, AI-dependent platform.
Market adoption speed is a key commercial risk.

Competitive Landscape

Competes with traditional flow cytometry companies (BD, Beckman Coulter) and advanced analysis firms (Cytek). Differentiates through unique label-free, high-throughput morphological sorting enabled by proprietary AI and the Ghost Cytometry method.

More companies in Japan →